Deepika polineni

Dr. Deepika Polineni, MD, is a Pulmonary Disease specialist in Kansas City, Kansas. She attended and graduated from University Of Missouri, Kansas City, School Of Medicine in 2004, having over 19 years of diverse experience, especially in Pulmonary Disease.

Deepika Polineni, MD at 4000 Cambridge St, Kansas City, KS 66160. Get Deepika Polineni, MD can be contacted at (913) 588-1227. Get Deepika Polineni, MD reviews, rating, hours, phone number, directions and more.Rationale: The severity of cystic fibrosis (CF) lung disease varies widely, even for Phe508del homozygotes. Heritability studies show that more than 50% of the variability reflects non-cystic fibrosis transmembrane conductance regulator (CFTR) genetic variation; however, the full extent of the pertinent genetic variation is not known.Objectives: We sought to identify novel CF disease-modifying ...Peter J. Barry, Marcus A. Mall, Antonio Álvarez, Carla Colombo, Karin M. de Winter-De Groot, Isabelle Fajac, Kimberly A. McBennett, Edward F. McKone, Bonnie W ...Dr. Leonard Riley is a pulmonologist in Kansas City, KS and is affiliated with multiple hospitals in the area, including Kansas City Veterans Affairs Medical Center and the University of Kansas Health System. He received his medical degree from Ross University School of Medicine and has been in practice 3 years.Author links open overlay panel Amik Sodhi MBBS, MPH a, Katherine Cox-Flaherty MD b, Meredith Kendall Greer MD c, Tasnim I. Lat DO d, Yuqing Gao MD e, Deepika Polineni MD f, Margaret A. Pisani MD, MPH g, Ghada Bourjeily MD b, Marilyn K. Glassberg MD e, Carolyn D'Ambrosio MD g

- Deepika Polineni, MD, MPH - mRNA Therapy as a Treatment for CF - DB Sanders, MD - Pulmonary Exacerbations in the Era of Highly Effective CFTR Modulators - Jennifer Taylor-Cousar, MD, MSCS - Until It's Done For Everyone: Diversity, Inclusion and Equity in CF Care and ResearchChildren's Mercy Kansas City SHARE @ Children's Mercy Manuscripts, Articles, Book Chapters and Other Papers 4-12-2019 Aztreonam Lysine Inhalation Solution in Cystic Fibrosis.Internal Advisory Board. Members of the Kansas Institute for Precision Medicine leadership teams.Cystic fibrosis is a monogenic disease considered to affect at least 100 000 people worldwide. Mutations in CFTR, the gene encoding the epithelial ion channel that normally transports chloride and bicarbonate, lead to impaired mucus hydration and clearance. Classical cystic fibrosis is thus characterised by chronic pulmonary infection and inflammation, pancreatic exocrine insufficiency, male ...Deepika Polineni's 56 research works with 2,604 citations and 3,348 reads, including: Genetic therapies in cystic fibrosisDeepika Polineni 1 2 , Annalisa V Piccorelli 3 4 , William B Hannah 1 , Sarah N Dalrymple 1 , Rhonda G Pace 1 , Peter R Durie 5 6 7 , Simon C Ling 6 7 , Michael R Knowles 1 , Jaclyn R Stonebraker 1 AffiliationsDr. Margaret Leigh is a Pediatric Pulmonologist in Chapel Hill, NC. Find Dr. Leigh's phone number, address, insurance information, hospital affiliations and more.Deepika Polineni, MD, MPH. Associate Professor of Pediatrics, Allergy and Pulmonary Medicine Director, Cystic Fibrosis Center. Click ...

Deepika Polineni, Saint Louis, Missouri, United States of America Michal Schteinberg , Haifa, Israel Bashar Staitieh , Atlanta, Georgia, United States of AmericaOverall, studies demonstrated that inhaled aztreonam is a safe and effective antimicrobial treatment for the eradication of newly acquired P. aeruginosa and long-term suppressive therapy of chronic endobronchial infection among people with cystic fibrosis. Keywords: Cystic fibrosis, aztreonam lysine, inhalation, Pseudomonas.Deepika Polineni. Search for articles by this author, + Author Affiliations. 1 Department of Pediatrics University of Colorado Anschutz Medical Campus Aurora, Colorado and; 2 Department of Internal Medicine University of Kansas School of Medicine Kansas City, Kansas ...Dr. Garry R. Cutting is a Clinical Geneticist in Baltimore, MD. Find Dr. Cutting's phone number, address, insurance information, hospital affiliations and more.

Attribution in journalism.

That's because the improved survival overall," University of Kansas Health System Pulmonologist Deepika Polineni said. For Carollo and doctors alike, this medical breakthrough feels like a ...Deepika Polineni. x. Deepika Polineni. Search for articles by this author. ,. + Author Affiliations. 1Department of Pediatrics University of Colorado Anschutz ...Liked by Deepika Polineni. At the age of 23 she founded Tinder but after 2 years she was forced to leave the company because she was a victim of sexual harassment. At 25 she…. Deborah Friedman 1 , Beth A Smith 2 3 , Amanda Bruce 4 , Carolyn E Schwartz 5 6 , Hang Lee 7 , Hanna Pinsky 8 , Elizabeth Gootkind 8 , Margot Hardcastle 8 , Nicole Shea 2 , Christine M Roach 2 , Caitlin Miller 2 , Deepika Polineni 9 , Matthias Salathe 9 , Alexandra L Quittner 10 , Anna M Georgiopoulos 1The data show sustainment of the historic improvements in lung function, respiratory symptoms and sweat chloride, a marker of CFTR function,” said Deepika Polineni, M.D., MPH, Associate Professor of Pediatrics and Cystic Fibrosis Center Director at Washington University School of Medicine in St. Louis, and a co-investigator of the 445-105 ...

On #NationalWomenPhysiciansDay, we recognize and thank pioneering women like Dr. Dorothy Hansine Andersen who wrote the first comprehensive medical report on #cysticfibrosis.Polineni D, Piccorelli AV, Hannah WB, Dalrymple SN, Pace RG, Durie PR, Ling SC, Knowles MR, Stonebraker JR. Analysis of a large cohort of cystic fibrosis patients with severe liver disease indicates lung function decline does not significantly differ from that of the general cystic fibrosis population. PLoS One. 2018 Oct 11;13(10):e0205257. doi: 10.1371/journal.pone.0205257. eCollection 2018.Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trialsCheryl L. Jernigan, CPA, FACHE (PACE) Survivor of Breast Cancer, co-Survivor of HPV Tonsil Cancer & Metastatic Prostate Cancer Lead Patient Advocate & Co-Leader, Patient and Community Engagement, Kansas Institute for Precision Medicine COBREotypes. However, a significant proportion of the CF population is in need of alternative treatment strategies to address CFTR variants that are ineligible for therapeutic protein correction and/or potentiation. Current drug development efforts of nucleic-acid based therapies (i.e., DNA and RNA based therapies) in CF are informed by historic challenges of CF gene therapy trials, recent FDA ...n in CF. We evaluated whether therapy with the CFTR modulator combination lumacaftor/ivacaftor (luma/iva) has a beneficial impact on SIBO as measured by breath testing (BT). Methods: A multicenter longitudinal study of CFTR-dependent disease profiling (NCT02477319) included a prospective evaluation for SIBO by BT. Tidal breath samples were collected after fasting and 15, 30, 45, 60, 90, and ...Adam J. Shapiro1, Maureen Josephson2, Margaret Rosenfeld3, Ozge Yilmaz4, Stephanie D. Davis5, Deepika Polineni6, Elena Guadagno7, Margaret W. Leigh8 and Valery Lavergne9 1Division of Pediatric Respiratory Medicine, Montreal Children's Hospital, McGill University Health Centre Research Institute, Montreal,A few months and a global pandemic later, he's partnered with pulmonologist Deepika Polineni, MD, MPH, associate professor in the KU School of Medicine, and they have launched a trial together exploring a drug to fight COVID-19. ... Gan reached out to Polineni to partner as co-investigator. Together, the two researchers reached out to Aclaris ...Patients with cystic fibrosis have increased risk of pulmonary infections, and reducing spread of microorganisms is critical. To improve hospital-staff adherence to infection control guidelines, we implemented brightly colored Safe Zone floor decals, staff compliance contracts, and an infection control in-service video.

Semantic Scholar profile for Deepika Polineni, with 3 scientific research papers.

The data show sustainment of the historic improvements in lung function, respiratory symptoms and sweat chloride, a marker of CFTR function,” said Deepika Polineni, M.D., MPH, Associate Professor of Pediatrics and Cystic Fibrosis Center Director at Washington University School of Medicine in St. Louis, and a co-investigator of the …Physician-scientists Gregory Gan and Deepika Polineni, who research cancer and cystic fibrosis, have teamed up to test a new drug with the potential to keep COVID-19 patients from needing a ventilator.A few months and a global pandemic later, he's partnered with pulmonologist Deepika Polineni, M.D., MPH, and they have launched a trial together exploring a drug to fight COVID-19. From cancer to ...Dr. Deepika Polineni in Kansas City, MO Address: 64 East 54Th Street, Kansas City, MO 64112 Phone: (734) 945 2441; Please call Dr. Deepika at (913) 588 1227 to schedule an appointment in Kansas City KS or get more information.Deepika Polineni, M.D., MPH, co-led a study showing that Trikafta can provide additional benefit for CF patients who have genetic mutations that made them eligible for previously approved CFTR modulators. Since the U.S. Food and Drug Administration approved a breakthrough drug for cystic fibrosis (CF) in 2019, the media has been full of joyful ...There is now ample evidence that differences in sex and gender contribute to the incidence, susceptibility, presentation, diagnosis, and clinical course of many lung diseases. Some conditions are more prevalent in women, such as pulmonary arterial hypertension and sarcoidosis. Some life stages—such as pregnancy—are unique to women and can affect the onset and course of lung disease.Visit findatopdoc.com for all information on Dr. Deepika Polineni M.D., Pulmonologist | Pulmonary Disease in KANSAS CITY, MO, 64112. Profile, Reviews, Appointments ...Get reviews, hours, directions, coupons and more for Deepika Polineni, MD at 10710 Nall Ave, Overland Park, KS 66211. Search for other Physicians & Surgeons in Overland Park on The Real Yellow Pages®.

Nebraska 2007 football schedule.

Dreamcore roblox outfits.

Physician-scientists Gregory Gan and Deepika Polineni, who research cancer and cystic fibrosis, have teamed up to test a new drug with the potential to keep COVID-19 patients from needing a ventilator.Rana Dajani, Zodwa Dlamini, Aparna Vasanthakumar, Deepika Polineni, Silvia Calo, Jaira Ferreira de Vasconcellos, Malak Abedalthagafi, Bertha Hidalgo, Carine Le Goff Frontiers Media SA Science Genetics NeurogenomicsDr. Jessica E. Pittman is a Pediatric Pulmonologist in Saint Louis, MO. Find Dr. Pittman's phone number, address, insurance information, hospital affiliations and more.3:30 pm - 4:25 pm mRNA Therapies for Cystic Fibrosis - Deepika Polineni, MD, MPH 4:25 pm - 5:30 pm Exhibitor Hall / Lounge Activities / Reception (In Person) 5:30 pm - 6:00 pm Buffet (In-Person) 6:00 pm - 7:15 pm CFRI Awards Celebration with Special Guests 7:30 pm - 9:30 pm Dance Party Sunday, July 30, 2023 (Virtual and Live)Dr. Raksha Jain is a Pulmonologist in Dallas, TX. Find Dr. Jain's phone number, address, insurance information, hospital affiliations and more.Deepika Polineni: This is really incredible because the studies that were done allow the therapy to be approved for people even if they only have one copy of the Delta F508 mutation. That means that eventually this treatment will be able to reach approximately 90% of people with cystic fibrosis.When 2020 began, Gregory Gan, M.D., Ph.D., was all set to dive into new research on treatment resistance and metastasis in head and neck cancer. A few months and a global pandemic later, he's partnered with pulmonologist Deepika Polineni, M.D., MPH, and they have launched a trial together exploring a drug to fight COVID-19.Disclosures. The following relevant financial relationships have been disclosed by faculty, and all have been mitigated by Pri-Med Institute. Deepika Polineni, MD, MPH: Advisor to Laurent Pharmaceuticals. Marrah Lachowicz-Scroggins, PhD: No relevant financial relationships disclosed. Charles Vega, MD, FAAFP (Moderator): Consultant to GlaxoSmithKline. Non …‪University of Kansas‬ - ‪‪Cited by 2,466‬‬ - ‪cystic fibrosis‬ - ‪lung inflammation‬ - ‪extracellular vesicles‬ - ‪primary ciliary dyskinesia‬Dr. Cori L. Daines is a Pediatric Pulmonologist in Tucson, AZ. Find Dr. Daines's phone number, address, insurance information, hospital affiliations and more.14 Ağu 2020 ... Deepika Polineni and Gregory Gan have launched a trial together exploring a drug that they hope can thwart the "cytokine storm" that causes ... ….

Deepika Polineni worked as an Assistant Professor for the University of Kansas Medical Center (KUMC) and in 2017 had a reported pay of $76,659.18 according to public records. This is 4.9 percent higher than the average pay for university and college employees and 10.5 percent higher than the national average for government employees.Nasal lavage exosome analysis specifies therapeutic targets for precision treatment in cystic fibrosis Polineni, Deepika University of Kansas, Kansas City, KS, United StatesThe Lancet Respiratory Medicine (IF 76.2) Pub Date: 2023-09-09 , DOI: 10.1016/s2213-2600(23)00297-7 Nicole Mayer-Hamblett, John Paul Clancy, Raksha Jain, Scott H Donaldson, Isabelle Fajac, Christopher H Goss, Deepika Polineni, Felix Ratjen, Bradley S Quon, Edith T Zemanick, Scott C Bell, Jane C Davies, Manu Jain, Michael W Konstan, Natanya R Kerper, Tré LaRosa, Marcus A Mall, Edward McKone ...Abstract. Patients with cystic fibrosis have increased risk of pulmonary infections, and reducing spread of microorganisms is critical. To improve hospital-staff adherence to infection control guidelines, we implemented brightly colored Safe Zone floor decals, staff compliance contracts, and an infection control in-service video.31 Eki 2019 ... Then while on vacation in Colorado, she received a phone call from Deepika Polineni, M.D., MPH, assistant professor of internal medicine in the ...Dr. Raksha Jain is a board certified pulmonary and critical care physician in Dallas, TX and is affiliated with multiple hospitals in the area, including University of Texas Southwestern Medical Center and Children's Medical Center Dallas. She received her medical degree from University of Texas Houston Health Science Center, completed Internal ...Dr. Leonard Riley is a pulmonologist in Kansas City, KS and is affiliated with multiple hospitals in the area, including Kansas City Veterans Affairs Medical Center and the University of Kansas Health System. He received his medical degree from Ross University School of Medicine and has been in practice 3 years.Received: 7 May 2018 | Accepted: 18 June 2018 DOI: 10.1002/ppul.24127 REVIEW Overcoming psychosocial challenges in cystic fibrosis: Promoting resilience Emily F. Muther1 | Deepika Polineni2 | Greg S. Sawicki3 1University of Colorado School of Medicine, Aurora, ColoradoDeepika Polineni: This is really incredible because the studies that were done allow the therapy to be approved for people even if they only have one copy of the Delta F508 mutation. That means that eventually this treatment will be able to reach approximately 90% of people with cystic fibrosis. Deepika polineni, [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1], [text-1-1]